Is This Big Pharma Giant Headed for Another Breakup?

Generic drugmakers Actavis, Valeant, and Mylan are all reportedly interested in Pfizer's generic drug business. Will Pfizer play ball and sell off yet another one of its slower-growth units?

Jan 17, 2014 at 6:30PM

Pfizer's (NYSE:PFE) been all too happy to get rid of its peripheral businesses in the recent past, spinning off its animal health business in early 2013 after selling its infant nutrition group back in 2012. It's paid off in a big way for investors, who have made the most of Pfizer's stock surge over the past year. Could Pfizer be ready to divest yet another business in 2014?

Generic drugmakers are reportedly lining up for just that possibility. According to a recent Reuters reportMylan (NASDAQ:MYL)Actavis (NYSE:AGN), and Valeant Pharmaceuticals (NYSE:VRX) are all circling Pfizer's generics business now that the big pharma company's finished reorganizing. Pfizer's made no secret about its goal of honing in on its core branded pharmaceuticals business, and these three generics suitors all have been on the acquisitions train as of late.

Yet would Pfizer's lucrative generics business make sense for these suitors? In the video below, Motley Fool contributor Dan Carroll digs into the reported interest of these companies in a buy -- and how such a deal between Pfizer and one of these big names could mean big money for investors in the near future.

The tools you need to spark your financial future
Pfizer's hoping to keep its stock surge going in the new year, but have you made the most of the market's rally? Millions of Americans have waited on the sidelines since the market meltdown in 2008 and 2009, too scared to invest and put their money at further risk. Yet those who've stayed out of the market have missed out on huge gains and put their financial futures in jeopardy. In our brand-new special report, "Your Essential Guide to Start Investing Today," The Motley Fool's personal finance experts show you why investing is so important and what you need to do to get started. Click here to get your copy today -- it's absolutely free.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers